Table 2.
Adjusted hazard ratios and 95% confidence intervals for all-cause mortality according to time since diagnosis and clinical characteristics at breast cancer diagnosis
| Cancer-free |
Survivors |
|||
|---|---|---|---|---|
| Time since breast cancer diagnosis | Events/PT | HR (95% CI)a | Events/PT | HR (95% CI)a |
| Overall | ||||
| 0-5 y | 191/13 900 | 1.00 (ref) | 70/2694 | 1.91 (1.45 to 2.52) |
| >5-15 y | 371/16 726 | 1.00 (ref) | 110/2924 | 1.70 (1.37 to 2.11) |
| >15 y | 137/4620 | 1.00 (ref) | 37/716 | 1.84 (1.28 to 2.66) |
| Pinteractionb | — | .91 | ||
| Clinical characteristics | ||||
| Stage I | ||||
| 0-5 y | 191/13 900 | 1.00 (ref) | 28/1619 | 1.27 (0.85 to 1.90) |
| >5-15 y | 371/16 726 | 1.00 (ref) | 61/1766 | 1.55 (1.18 to 2.04) |
| >15 y | 137/4620 | 1.00 (ref) | 23/418 | 1.93 (1.24 to 3.00) |
| Pinteractionb | — | .17 | ||
| Stage II or III | ||||
| 0-5 y | 191/13 900 | 1.00 (ref) | 40/1035 | 2.81 (1.99 to 3.96) |
| >5-15 y | 371/16 726 | 1.00 (ref) | 48/1106 | 1.98 (1.45 to 2.70) |
| >15 y | 137/4620 | 1.00 (ref) | 14/269 | 1.93 (1.09 to 3.40) |
| Pinteractionb | — | .47 | ||
| ER-positive | ||||
| 0-5 y | 191/13 900 | 1.00 (ref) | 45/1993 | 1.66 (1.20 to 2.31) |
| >5-15 y | 371/16 726 | 1.00 (ref) | 84/2114 | 1.81 (1.42 to 2.30) |
| >15 y | 137/4620 | 1.00 (ref) | 29/507 | 2.11 (1.42 to 3.15) |
| Pinteractionb | — | .36 | ||
| Age ≥70 y | ||||
| 0-5 y | 147/4649 | 1.00 (ref) | 41/902 | 1.44 (1.01 to 2.04) |
| >5-15 y | 246/4292 | 1.00 (ref) | 70/717 | 1.76 (1.35 to 2.30) |
| >15 y | 64/635 | 1.00 (ref) | 14/54 | 2.69 (1.59 to 4.55) |
| Pinteractionb | — | .05 | ||
a
Adjusted for age (years), menopausal status (premenopausal, postmenopausal), education (<12, 12, >12 years), smoking status (never, former, current), alcohol intake (<3 drinks/mo, ≥1 drinks/wk), body mass index (<25, 25 to <30, ≥30 kg/m2), and oral hormone use (ever, never) using inverse probability weighting. CI = confidence interval; ER = estrogen receptor; HR = hazard ratio; PT = person-time in years.
b
P value for interaction between breast cancer status and time.